Menu Close

Yuhan out-licenses lung cancer drug to Janssen

[THE INVESTOR] Korean pharmaceutical company Yuhan said on Nov. 5 that it has signed a deal with Janssen Biotech to license out Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer. (본문 전체 11/5/2018 4:56 PM)